141 related articles for article (PubMed ID: 29843086)
1. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
Bode MF; Auriemma AC; Grover SP; Hisada Y; Rennie A; Bode WD; Vora R; Subramaniam S; Cooley B; Andrade-Gordon P; Antoniak S; Mackman N
Thromb Res; 2018 Jul; 167():128-134. PubMed ID: 29843086
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Liu J; Nishida M; Inui H; Chang J; Zhu Y; Kanno K; Matsuda H; Sairyo M; Okada T; Nakaoka H; Ohama T; Masuda D; Koseki M; Yamashita S; Sakata Y
J Atheroscler Thromb; 2019 Oct; 26(10):915-930. PubMed ID: 30867376
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways.
Zhang Q; Zhang Z; Chen W; Zheng H; Si D; Zhang W
PeerJ; 2023; 11():e16097. PubMed ID: 37786576
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice.
Narita M; Hanada K; Kawamura Y; Ichikawa H; Sakai S; Yokono Y; Senoo M; Narita N; Shimada M; Osanai T; Okumura K; Tomita H
Hypertens Res; 2021 Oct; 44(10):1261-1273. PubMed ID: 34285375
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice.
Nakanishi N; Kaikita K; Ishii M; Oimatsu Y; Mitsuse T; Ito M; Yamanaga K; Fujisue K; Kanazawa H; Sueta D; Takashio S; Arima Y; Araki S; Nakamura T; Sakamoto K; Suzuki S; Yamamoto E; Soejima H; Tsujita K
Circ Rep; 2020 Mar; 2(3):158-166. PubMed ID: 33693223
[No Abstract] [Full Text] [Related]
6. Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.
Hara T; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Eur J Pharmacol; 2018 Feb; 820():222-228. PubMed ID: 29269019
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban, a Direct Factor Xa Inhibitor, Ameliorates Hypertensive Renal Damage Through Inhibition of the Inflammatory Response Mediated by Protease-Activated Receptor Pathway.
Ichikawa H; Shimada M; Narita M; Narita I; Kimura Y; Tanaka M; Osanai T; Okumura K; Tomita H
J Am Heart Assoc; 2019 Apr; 8(8):e012195. PubMed ID: 30957622
[TBL] [Abstract][Full Text] [Related]
8. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.
Imano H; Kato R; Tanikawa S; Yoshimura F; Nomura A; Ijiri Y; Yamaguchi T; Izumi Y; Yoshiyama M; Hayashi T
J Pharmacol Sci; 2018 Jul; 137(3):274-282. PubMed ID: 30055890
[TBL] [Abstract][Full Text] [Related]
9. Direct Rivaroxaban-Induced Factor XA Inhibition Proves to be Cardioprotective in Rats.
Guillou S; Beaumont J; Tamareille S; Giraud S; Mirebeau-Prunier D; Prunier F; Macchi L
Shock; 2020 Jun; 53(6):730-736. PubMed ID: 31348147
[TBL] [Abstract][Full Text] [Related]
10. Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation.
Kondo H; Abe I; Fukui A; Saito S; Miyoshi M; Aoki K; Shinohara T; Teshima Y; Yufu K; Takahashi N
J Cardiol; 2018 Mar; 71(3):310-319. PubMed ID: 28993090
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban Inhibits Angiotensin II-Induced Activation in Cultured Mouse Cardiac Fibroblasts Through the Modulation of NF-κB Pathway.
Hashikata T; Yamaoka-Tojo M; Namba S; Kitasato L; Kameda R; Murakami M; Niwano H; Shimohama T; Tojo T; Ako J
Int Heart J; 2015; 56(5):544-50. PubMed ID: 26370374
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
Chang CJ; Cheng CC; Chen YC; Higa S; Huang JH; Chen SA; Chen YJ
Eur J Pharmacol; 2018 Aug; 833():462-471. PubMed ID: 30017860
[TBL] [Abstract][Full Text] [Related]
13. Early initiation of a factor Xa inhibitor can attenuate tissue repair and neurorestoration after middle cerebral artery occlusion.
Komori M; Ago T; Wakisaka Y; Nakamura K; Tachibana M; Yoshikawa Y; Shibahara T; Yamanaka K; Kuroda J; Kitazono T
Brain Res; 2019 Sep; 1718():201-211. PubMed ID: 31103522
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice.
Goto M; Miura S; Suematsu Y; Idemoto Y; Takata K; Imaizumi S; Uehara Y; Saku K
Int J Cardiol; 2016 Oct; 220():602-7. PubMed ID: 27390997
[TBL] [Abstract][Full Text] [Related]
15. Demeanor of rivaroxaban in activated/inactivated FXa.
Seki K; Mizuno Y; Sakashita T; Nakano S; Tanno J; Okazaki Y; Muramatsu T; Nishimura S; Senbonmatsu T
J Pharmacol Sci; 2017 Mar; 133(3):156-161. PubMed ID: 28314697
[TBL] [Abstract][Full Text] [Related]
16. Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality.
Esteve-Pastor MA; Orenes-Piñero E; Roldán V; Lacunza-Ruiz J; Valdés M; Marín F
Cardiol J; 2018; 25(1):151-154. PubMed ID: 29512103
[No Abstract] [Full Text] [Related]
17. The role of rivaroxaban in left ventricular thrombi.
Abdelnaby M; Almaghraby A; Abdelkarim O; Saleh Y; Hammad B; Badran H
Anatol J Cardiol; 2019 Jan; 21(1):47-50. PubMed ID: 30587707
[No Abstract] [Full Text] [Related]
18. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice.
Wu TC; Chan JS; Lee CY; Leu HB; Huang PH; Chen JS; Lin SJ; Chen JW
Cardiovasc Diabetol; 2015 Jun; 14():81. PubMed ID: 26077117
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban does not affect growth of human pancreatic tumors in mice.
Maqsood A; Hisada Y; Garratt KB; Homeister J; Mackman N
J Thromb Haemost; 2019 Dec; 17(12):2169-2173. PubMed ID: 31393055
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin A inhibition attenuates myocardial infarction-induced heart failure on the functional and proteomic levels.
Petrera A; Gassenhuber J; Ruf S; Gunasekaran D; Esser J; Shahinian JH; Hübschle T; Rütten H; Sadowski T; Schilling O
J Transl Med; 2016 May; 14(1):153. PubMed ID: 27246731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
